Acrux Limited

ASX:ACR ISIN:AU000000ACR3

 Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products.  
 
     

查看其它語言版本

新聞

6月22日澳洲股市:打破跌勢

🕔6/22/2009 1:00:22 PM 18620

上週五,澳洲股市在一周之中首次收漲。基本指數S&P/ASX200上漲7.5點,或0.19%,報3,899.6點,綜合指數上漲7點,或0.18%,報3894.4點。

閱讀全文
###

48,014 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 23) (過去30日: 103) (自發布以來: 8101) 

公司詳細

    傳真
  • (03) 8379 0101 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.acrux.com.au

更多新聞紀錄

  • 2024/12/19: Change in substantial holding*
  • 2024/12/19: Cleansing Notice*
  • 2024/12/19: Application for quotation of securities - ACR*
  • 2024/12/17: Investor Deck update, SPP Closes 18 December 2024, 5pm*
  • 2024/12/16: Investor Webinar, Tuesday 17 December 2024 4pm AEDT*
  • 2024/12/13: Commercialisation of Nitroglycerin Ointment*
  • 2024/12/12: Cleansing Notice*
  • 2024/12/12: Application for quotation of securities - ACR*
  • 2024/12/12: Notification of cessation of securities - ACR*
  • 2024/12/12: Appendix 3Y - Oldham*
*refer to company website